Compare KeyCorp (KEY) vs Novavax Inc (NVAX) Price & Performance

KeyCorp (KEY) trades at $23.26, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Strong fundamentals include a 26.05% net income margin and 10.61% ROE, while valuation metrics show a P/E of 14.45 and P/B of 1.45. Recent corporate actions include consistent quarterly dividends of $0.21 per share and a new $3 billion buyback program announced in July 2026.

KEY presents a compelling investment case with analyst consensus pointing to significant upside (price target $30.50, 31% potential). The combination of earnings momentum, shareholder-friendly capital returns, and improving loan growth supports bullish sentiment. However, risks include potential pressure on net interest margins from Fed policy and competitive challenges in regional banking. The stock's current valuation appears reasonable relative to earnings growth prospects.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.